DPRs finalised for JBS-Medchal, JBS-Shameerpet, & RGIA
Hyderabad Airport Metro Limited (HAML) has informed that the Detailed Project Reports (DPRs) of the proposed Phase 2B of Hyderabad Metro Rail for JBS-Medchal, JBS-Shameerpet, and Airport - Future City Metro corridors — spanning 86.1 km with an estimated cost of ₹19,579 crore — have been finalised.
The DPRs for these proposed corridors for the next phase were prepared and approved by the Hyderabad Airport Metro Limited Board on May 8, 2025. They are currently under review by the State government, said Managing Director N.V.S. Reddy, in an official press release on Thursday (May 22, 2025).
18 stations on the 24.5 kms JBS- Medhcal route
The JBS Station - Medchal route will be a fully elevated corridor of 24.5 kilometers with 18 stations while the JBS Station - Shameerpet route will be a 22-kilometer corridor with 14 stations. This route will be 20.35 km of elevated section and 1.65 km underground of underground section near the Hakimpet Air Force Station.
1.5 km underground section at RGIA airport
The RGIA-Future City (Skill University) spans 39.6 kilometers, of which 1.5 km will be underground section from the RGIA airport, 21 km will be elevated and 17 km at grade or on ground. This route will be from the Shamshabad International Airport to Skills University via Pedda Golconda and Raviryala ORR exits.
The DPRs for these new corridors have been comprehensively prepared and submitted to the State government, keeping in view the Central government guidelines, metro rail construction estimates in other States, and traffic needs of the Hyderabad capital region, he said.
Full details would be out once the State government approves the DPRs and submits the proposal to the Central government . These reports have several aspects including transforming the JBS region into an international hub as per the directions of the Chief Minister A. Revanth Reddy, added the MD in the press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
an hour ago
- Indian Express
Mohali surgeon duped in online trading scam, loses Rs 91 lakh; Cyber Cell launches probe
A senior surgeon working at a renowned hospital in Mohali has fallen victim to a large-scale online trading scam. According to the complaint filed with the Punjab State Cyber Crime Cell, the doctor was defrauded of approximately Rs 91 lakh by unidentified cyber fraudsters. As per the information shared with the Cyber Crime Police Station, the doctor received an email from a Hyderabad-based company claiming to be S&W Aubrey Capital Management Investment Funds. Through this email communication, he was added to a WhatsApp group called MK-S&W India VIP-67080. The members of the group assured him of daily profits if he invested in their trading platform. From February 19, 2025, to the last week of May, the doctor transferred funds through various channels such as UPI, RTGS, and bank transfers. The money was sent to HDFC Bank, Bandhan Bank, and Bank of Baroda accounts. In total, nine major transactions amounting to nearly Rs 91 lakh were made. The doctor stated that when he attempted to withdraw his profits, his account was deleted, and all communication with the fraudsters was cut off. Based on the complaint and supporting evidence, the police have registered a case against unknown individuals under sections 318(4) and 61(2) of the Bharatiya Nyaya Sanhita (BNS), 2023, and sections 66(C) and 66(D) of the Information Technology Act, 2000. The Cyber Crime Cell has initiated a detailed investigation and issued a public warning to remain cautious of unknown investment platforms. The matter is being investigated thoroughly, and strict legal action will be taken against the culprits, said an official from the Cyber Crime Cell.
Mint
4 hours ago
- Mint
KKR, TPG eye Relisys Medical Devices in early-stage buyout talks
MUMBAI : Relisys Medical Devices is in early-stage discussions with global private equity firms KKR and TPG for a potential ₹1,200–1,300 crore investment, with the transaction likely to offer a full or partial exit to existing investor Siguler Guff, two people familiar with the matter told Mint. 'While TPG is evaluating the company to strengthen its portfolio, KKR is in discussions with the medical devices maker to build out its med-tech platform under which it acquired Healthium Medtech last year from Apax Funds," one of the people cited above said. TPG, too, may look at developing a med-tech platform of its own, the person added. A majority of the proceeds from the transaction, if it materialises, will likely be secondary in nature, enabling Siguler Guff to partially or fully exit. A smaller primary infusion may also be included to fund Relisys's expansion plans, said the second person. Both private equity firms are expected to seek a controlling stake in the Hyderabad-based medical devices maker. In secondary deals, existing shareholders sell their stakes to other investors and the company doesn't receive any new capital. Such shares are usually traded at a discount to primary equity. While KKR declined to comment, TPG, Siguler Guff, Healthium, and Relisys did not respond to Mint's mails sent on Sunday. Also read: Zydus bets big on vaccines and medtech In February, VCCircle had reported that o3 Capital, a mid-market investment bank, was advising Relisys in its search for potential buyers. The report also noted that existing investor Siguler Guff was exploring a full or partial exit, alongside the company's founders, in a transaction then estimated to be valued at $50–70 million ( ₹435–610 crore). Company background Founded in 1997 by technocrats and clinicians, Relisys Medical Devices manufactures cardiovascular products like drug-eluting stents, balloon catheters, diagnostic catheters, and transcatheter heart valves. It also acquired Multimedics in 2018 to expand its stent-making capabilities globally. In FY24, the company reported revenue of ₹169.4 crore, up slightly from ₹162.7 crore a year earlier. Net profit rose marginally to ₹36.3 crore, according to data from Tracxn. The bustling deal activity in the sector also underscores the growing investor appetite for med-tech companies in India. Some notable transactions include Meril Life Sciences $210 million funding from Warburg Pincus which also invested about $300 million in Appasamy Associates. SMT raised $150 million from Samara Capital while Translumina raised around $90 million from Everstone Capital. Also read: Health ministry to set up a panel to review medical device-related adverse events Sector outlook India's $12 billion med-tech market is projected to hit $50 billion by 2030, according to EY. Despite $3.8 billion in exports last fiscal, the country is still heavily import-dependent, with imports at $8.2 billion, making up 80–85% of domestic consumption. Growth is expected to be driven by rising income levels, wider insurance coverage, medical tourism, and rapid healthcare infrastructure expansion in Tier 2 and 3 cities. EY noted that global MNCs are increasingly choosing India for R&D, manufacturing, and global capability centers (GCCs)—further strengthening the ecosystem. Also read: India eyes global pharma dominance with a ₹5,000 crore revitalisation plan
Time of India
13 hours ago
- Time of India
Apollo Hospitals plans to sell maternity care arm
Apollo Hospitals Enterprises, India's largest private hospital chain, plans to sell Apollo Cradle and Children's Hospital (ACCHL), a chain of maternity and infant care hospitals , multiple people familiar with the development said. Apollo has hired Allegro Capital to find a buyer for the asset, which is likely to be valued at ₹1,000-1,200 crore, they said. The sale process has been launched and the banker has sounded out to a bunch of leading private equity funds . An email sent to Apollo Hospitals spokesperson for comments on Friday did not elicit any responses till the press time on Sunday. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Schlechter Stuhlgang? Diese Methode funktioniert wie "auf Knopfdruck" Darmschutz Ratgeber Undo ACCHL, a subsidiary of Apollo Specialty Hospitals, has about 363 beds under 13 hospitals across cities like Delhi, Bengaluru, Chennai, Hyderabad, Amritsar, Gurugram, Noida and Ghaziabad. For the year ended March 2024, ACCHL recorded a net loss of ₹17 lakh, according to Apollo's annual report. The mother and child care market in India is estimated at about ₹30,000 crore a year and is expected to grow 15% compounded annually over the next few years. The market is currently dominated by a handful of private hospitals such as Apollo Cradle, Hyderabad-based Rainbow Children's Medicare , and Bengaluru-based chains Motherhood, Cloudnine Hospitals and Kangaroo Care. Live Events British International Investment Plc-backed Rainbow got listed in 2022 and has a market cap of ₹14,260 crore as of Friday. Motherhood is backed by TPG Growth and Singapore's GIC, while Cloudnine is backed by domestic PE fund True North, TPG NewQuest, Temasek and Peak XV. Indira IVF, the country's largest fertility clinics chain owned by EQT Partners, entered into maternity and childcare with the launch of MatCare Maternity & Child Hospital in March. Private equity firm SeaLink Capital Partners and the promoters of Surya Children's Medicare are, meanwhile, looking to sell a majority stake in western India's largest children's hospital chain. A deal is expected to value the company at ₹1,000-1,200 crore, ET reported last year. As of March 31, 2024, Apollo Hospitals had a capacity of 10,134 beds across 73 hospitals in India and overseas. Of these, 8,710 beds are located in 45 owned hospitals, 271 beds in 11 daycare/short surgical stay centres, and 790 beds in six hospitals under management through operations and management contracts.
